Results 311 to 320 of about 2,195,321 (395)

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

American Journal of Hematology, EarlyView.
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley   +1 more source

Protocol for human evaluation of generative artificial intelligence chatbots in clinical consultations. [PDF]

PLoS One
Chiu EK, Chung TW.
europepmc   +1 more source

Principles of Soil Microbiology

, 1928
Selman A. Waksman
openalex   +2 more sources

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review

American Journal of Hematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley   +1 more source

Erratum for Zhang et al., "Evaluating the stability of nursery-established arbuscular mycorrhizal fungal associations in apple rootstocks". [PDF]

Appl Environ Microbiol
Zhang H, Wang W, Honaas L, Mazzola M, Somera T.   +4 more
europepmc   +1 more source

Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis

American Journal of Hematology, EarlyView.
ABSTRACT In the Phase 3 DREAMM‐7 study of patients with relapsed/refractory multiple myeloma (RRMM) who received ≥ 1 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated a progression‐free survival (PFS) benefit versus daratumumab plus bortezomib and dexamethasone (DVd).
Joshua Richter, Ajay Nooka, Paula Rodríguez‐Otero, Fredrik Schjesvold, Eirini Katodritou, Emily Combe, Marianne Scott, Leanne Cooper, Indeg Sly, Nick Ballew, Jacopo Bitetti, Natalie Boytsov, Molly Purser, Simon McNamara   +13 more
wiley   +1 more source

THE MICROBIOLOGICAL DETERMINATION OF AMINO ACIDS

, 1943
K.A. Kuiken, William H. Norman, Carl M. Lyman, Fred Hale, Lois Blotter   +4 more
openalex   +1 more source

Topics of Interest in Women With Myeloproliferative Neoplasms

American Journal of Hematology, EarlyView.
Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber, Paola Guglielmelli, Naseema Gangat   +2 more
wiley   +1 more source

Retrieval-augmented generation salvages poor performance from large language models in answering microbiology-specific multiple-choice questions. [PDF]

J Clin Microbiol
Perkins G, Anderson NW, Spies NC.
europepmc   +1 more source

THE MICROBIOLOGICAL ASSAY OF TRYPTOPHANE IN PROTEINS AND FOODS

, 1944
Richard D. Greene, A. Black
openalex   +1 more source